Choosing the Right Therapy at the Right Time for Pediatric Inflammatory Bowel Disease
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Choosing the Right Therapy at the Right Time for Pediatric Inflammatory Bowel Disease
Authors
Keywords
-
Journal
GASTROENTEROLOGY CLINICS OF NORTH AMERICA
Volume 52, Issue 3, Pages 517-534
Publisher
Elsevier BV
Online
2023-08-03
DOI
10.1016/j.gtc.2023.05.006
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Guselkumab for the treatment of Crohn’s disease: Induction results from the Phase 2 GALAXI-1 study
- (2022) William J. Sandborn et al. GASTROENTEROLOGY
- Failure to Achieve Target Drug Concentrations During Induction and Not HLA-DQA1*05 Carriage is Associated with Anti-Drug Antibody Formation in Patients with Inflammatory Bowel Disease
- (2022) Elizabeth A. Spencer et al. GASTROENTEROLOGY
- Inflammatory Bowel Disease Patients’ Treatment Preferences Using a Discrete Choice Experiment Technique: The InPuT Study
- (2022) Stefan Schubert et al. ADVANCES IN THERAPY
- Tofacitinib Appears Well Tolerated and Effective for the Treatment of Patients with Refractory Crohn’s Disease
- (2022) Scott David Lee et al. DIGESTIVE DISEASES AND SCIENCES
- Neutralizing anti-GM-CSF autoantibodies recognize posttranslational glycosylations on GM-CSF years prior to diagnosis and predict complicated Crohn’s Disease.
- (2022) Arthur Mortha et al. GASTROENTEROLOGY
- Outcomes of Children with Inflammatory Bowel Disease who Develop Anti-tumour Necrosis Factor-induced Skin Reactions
- (2022) Michael T Dolinger et al. Journal of Crohns & Colitis
- Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
- (2022) Eric L. Simpson et al. JAMA Dermatology
- Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
- (2022) Bruce E Sands et al. LANCET
- Patients Undergoing Abdominal Operation for Crohn’s Disease Have Lower Mortality and Readmission Rate at High-Volume Hospital Centers
- (2022) Hannah Williams et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe Crohn’s disease: an open-label multicentre randomised controlled trial
- (2021) Maria M E Jongsma et al. GUT
- Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
- (2021) Waseem Ahmed et al. Clinical Gastroenterology and Hepatology
- Approach to the management of recently diagnosed inflammatory bowel disease patients: a user’s guide for adult and pediatric gastroenterologists
- (2021) Manasi Agrawal et al. GASTROENTEROLOGY
- 456 EFFICACY, SAFETY AND MUCOSAL HEALING OF EARLY VERSUS LATE USE OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
- (2021) Séverine Vermeire et al. GASTROENTEROLOGY
- Vedolizumab and Anti-TNFα Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
- (2021) Brian Bressler et al. Journal of Crohns & Colitis
- Results of the Seventh Scientific Workshop of ECCO: Precision medicine in IBD - disease outcome and response to therapy
- (2021) Bram Verstockt et al. Journal of Crohns & Colitis
- Patient Preferences for Subcutaneous versus Intravenous Administration of Treatment for Chronic Immune System Disorders: A Systematic Review
- (2021) Paul M Overton et al. Patient Preference and Adherence
- MiMeNet: Exploring microbiome-metabolome relationships using neural networks
- (2021) Derek Reiman et al. PLoS Computational Biology
- Breaking the therapeutic ceiling in drug development in ulcerative colitis
- (2021) Dahham Alsoud et al. Lancet Gastroenterology & Hepatology
- Molecular characterization of limited ulcerative colitis reveals novel biology and predictors of disease extension
- (2021) Carmen Argmann et al. GASTROENTEROLOGY
- Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease
- (2021) Ruben J. Colman et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Impact of diagnostic delay to the clinical presentation and associated factors in pediatric inflammatory bowel disease: a retrospective study
- (2021) Emmiina Sulkanen et al. BMC GASTROENTEROLOGY
- Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials
- (2021) David T Rubin et al. Lancet Gastroenterology & Hepatology
- Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study
- (2021) Silvio Danese et al. Lancet Gastroenterology & Hepatology
- Intravenous versus subcutaneous delivery of biotherapeutics in IBD: an expert’s and patient’s perspective
- (2021) Laimas Jonaitis et al. BMC Proceedings
- Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohnʼs Disease in the United States
- (2020) Corey A. Siegel et al. Clinical and Translational Gastroenterology
- The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti-tumour necrosis factor
- (2020) Hadrien Alric et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment
- (2020) Vince B. C. Biemans et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease
- (2020) Ryan C. Ungaro et al. GASTROENTEROLOGY
- Impact of immune-mediated diseases in inflammatory bowel disease and implications in therapeutic approach
- (2020) M. J. García et al. Scientific Reports
- Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial
- (2020) Toer W Stevens et al. Lancet Gastroenterology & Hepatology
- Ustekinumab for Perianal Crohn's Disease
- (2020) Constance Chapuis-Biron et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab
- (2020) Liza Kassouri et al. DIGESTIVE AND LIVER DISEASE
- Thiopurines in Pediatric Inflammatory Bowel Disease: Current and Future Place
- (2020) Karen van Hoeve et al. PEDIATRIC DRUGS
- Pharmacogenetics in Psychiatry: An Update on Clinical Usability
- (2020) Ron H. N. van Schaik et al. Frontiers in Pharmacology
- Risk factors and long-term outcome of disease extent progression in Asian patients with ulcerative colitis: a retrospective cohort study
- (2019) Yun Qiu et al. BMC GASTROENTEROLOGY
- Shorter Disease Duration is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn’s Disease but Not Ulcerative Colitis
- (2019) David M. Faleck et al. Clinical Gastroenterology and Hepatology
- Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice
- (2019) Graham J. Britton et al. IMMUNITY
- Cost-effectiveness of laparoscopic ileocaecal resection versus infliximab treatment of terminal ileitis in Crohn’s disease: the LIR!C Trial
- (2019) E Joline de Groof et al. GUT
- Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry
- (2019) Elke Schaeffeler et al. GENETICS IN MEDICINE
- P030 DELAYED DIAGNOSIS OF CROHN’S DISEASE IS COMMON AND ASSOCIATED WITH AN INCREASED RISK OF DISEASE COMPLICATIONS
- (2019) Zane Gallinger et al. GASTROENTEROLOGY
- Patients Who Undergo Colectomy for Pediatric Ulcerative Colitis at Low-volume Hospitals Have More Complications
- (2019) Matthew D. Egberg et al. Clinical Gastroenterology and Hepatology
- Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease
- (2019) Nicholas A. Kennedy et al. Clinical Gastroenterology and Hepatology
- A blood-based prognostic biomarker in IBD
- (2019) Daniele Biasci et al. GUT
- Single-Cell Analysis of Crohn’s Disease Lesions Identifies a Pathogenic Cellular Module Associated with Resistance to Anti-TNF Therapy
- (2019) Jerome C. Martin et al. CELL
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating the cost-effectiveness of early compared to late or no biologic treatment to manage Crohn’s disease using real world data
- (2019) Nadia Pillai et al. Journal of Crohns & Colitis
- HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease
- (2019) Aleksejs Sazonovs et al. GASTROENTEROLOGY
- Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies
- (2018) Edouard J. Louis et al. ADVANCES IN THERAPY
- Expansion of IL-23 receptor bearing TNFR2+ T cells is associated with molecular resistance to anti-TNF therapy in Crohn’s disease
- (2018) Heike Schmitt et al. GUT
- Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn’s Disease: Results from IMAgINE 1 and IMAgINE 2
- (2018) Frank M Ruemmele et al. Journal of Crohns & Colitis
- Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease
- (2018) Joanne E.Brady et al. CLINICAL THERAPEUTICS
- Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease
- (2018) Marla C Dubinsky et al. INFLAMMATORY BOWEL DISEASES
- Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations
- (2018) Amit V. Khera et al. NATURE GENETICS
- A 10-Year Follow-up Study of the Natural History of Perianal Crohn’s Disease in a Danish Population-Based Inception Cohort
- (2018) Mirabella Zhao et al. INFLAMMATORY BOWEL DISEASES
- GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD
- (2018) Tim Dierckx et al. Journal of Crohns & Colitis
- Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response
- (2018) Yael Haberman et al. Nature Communications
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease
- (2017) Joseph D. Feuerstein et al. GASTROENTEROLOGY
- The Crohnʼs and Colitis Foundation of America Survey of Inflammatory Bowel Disease Patient Health Care Access
- (2017) David T. Rubin et al. INFLAMMATORY BOWEL DISEASES
- A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease
- (2017) Ditte V Mogensen et al. Journal of Crohns & Colitis
- DOP025 Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
- (2017) S. Tadbiri et al. Journal of Crohns & Colitis
- GlycA, a novel biomarker of systemic inflammation and cardiovascular disease risk
- (2017) Margery A. Connelly et al. Journal of Translational Medicine
- Crohn's disease
- (2017) Joana Torres et al. LANCET
- Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study
- (2017) Subra Kugathasan et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- A functional genomics predictive network model identifies regulators of inflammatory bowel disease
- (2017) Lauren A Peters et al. NATURE GENETICS
- Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease
- (2017) James C Lee et al. NATURE GENETICS
- Elevated C-reactive protein level during clinical remission can predict poor outcomes in patients with Crohn’s disease
- (2017) Kyunghwan Oh et al. PLoS One
- Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study
- (2017) Ammar Hassanzadeh Keshteli et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Acute severe ulcerative colitis: latest evidence and therapeutic implications
- (2017) Parambir S. Dulai et al. Therapeutic Advances in Chronic Disease
- Serologic microbial associated markers can predict Crohn's disease behaviour years before disease diagnosis
- (2016) R. S. Choung et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Development of an index to define overall disease severity in IBD
- (2016) Corey A Siegel et al. GUT
- Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis
- (2016) Marina Aloi et al. INFLAMMATORY BOWEL DISEASES
- Predicting Outcomes to Optimize Disease Management in Inflammatory Bowel Diseases
- (2016) Joana Torres et al. Journal of Crohns & Colitis
- NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
- (2016) Takaya Moriyama et al. NATURE GENETICS
- Extraintestinal manifestations of inflammatory bowel disease: Do they influence treatment and outcome?
- (2016) Fernando Tavarela Veloso WORLD JOURNAL OF GASTROENTEROLOGY
- Biomarkers of Inflammation in Inflammatory Bowel Disease
- (2015) Bruce E. Sands GASTROENTEROLOGY
- Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis
- (2015) Sanjay K. Murthy et al. INFLAMMATORY BOWEL DISEASES
- Infliximab “Top-Down” Strategy is Superior to “Step-Up” in Maintaining Long-Term Remission in the Treatment of Pediatric Crohn Disease
- (2015) Yoo Min Lee et al. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
- Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial
- (2015) Reena Khanna et al. LANCET
- Decreased Plasma Histidine Level Predicts Risk of Relapse in Patients with Ulcerative Colitis in Remission
- (2015) Tadakazu Hisamatsu et al. PLoS One
- Catching the Therapeutic Window of Opportunity in Early Crohn’s Disease
- (2014) Silvio Danese et al. CURRENT DRUG TARGETS
- Decreasing trends in hospitalizations during anti-TNF therapy are associated with time to anti-TNF therapy: Results from two referral centres
- (2014) Michael D. Mandel et al. DIGESTIVE AND LIVER DISEASE
- Exam 1: Increased Effectiveness of Early Therapy With Anti–Tumor Necrosis Factor-α vs an Immunomodulator in Children With Crohn's Disease
- (2013) GASTROENTEROLOGY
- Granulocyte–Macrophage Colony-Stimulating Factor Autoantibodies
- (2013) Grace Gathungu et al. INFLAMMATORY BOWEL DISEASES
- Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy
- (2013) Martine De Vos et al. INFLAMMATORY BOWEL DISEASES
- Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study
- (2012) Mirthe Emilie van der Valk et al. GUT
- Subgroup analysis of the placebo-controlled CHARM trial: Increased remission rates through 3years for adalimumab-treated patients with early Crohn's disease
- (2012) S. Schreiber et al. Journal of Crohns & Colitis
- Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options
- (2011) Corey A Siegel GUT
- Ulcerative Colitis as A Progressive Disease: The Forgotten Evidence
- (2011) Joana Torres et al. INFLAMMATORY BOWEL DISEASES
- Frequency and Risk Factors for Extraintestinal Manifestations in the Swiss Inflammatory Bowel Disease Cohort
- (2010) Stephan R Vavricka et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
- (2010) Stefan Schreiber et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Early Crohn disease: a proposed definition for use in disease-modification trials
- (2010) L. Peyrin-Biroulet et al. GUT
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario
- (2010) Lee S Roth WORLD JOURNAL OF GASTROENTEROLOGY
- Risk factors and characteristics of extent progression in ulcerative colitis
- (2009) María Josefina Etchevers et al. INFLAMMATORY BOWEL DISEASES
- Natural history of Crohnʼs disease
- (2009) Bénédicte Pigneur et al. INFLAMMATORY BOWEL DISEASES
- Granulocyte-Macrophage Colony-Stimulating Factor Autoantibodies in Murine Ileitis and Progressive Ileal Crohn's Disease
- (2008) Xiaonan Han et al. GASTROENTEROLOGY
- C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study
- (2008) M Henriksen et al. GUT
- Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial
- (2008) Geert D'Haens et al. LANCET
- Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)
- (2008) Inger Camilla Solberg et al. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started